RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: In this study we compared the effectiveness between half energy photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) injection for chronic central serous chorioretinopathy (CSC). Methods: Forty-five eyes of 42 patients diagnosed as chronic CSC from March 2008 to April 2011 were treated with half energy PDT or IVB injection. The subjects were chosen for a retrospective study and analysis was performed on changes in best corrected visual acuity and existence of subretinal fluid, recurrence rate and changes in central macular thickness. Results: Similar improvement of visual acuity was observed in both treatment groups 1 month after treatment and no meaningful difference was found in each stage for both groups (p = 0.001, p = 0.0012, respectively). However, 6 to 12 months after the treatment, the half energy PDT group showed more improvement in visual acuity compared to the IVB injection group (p = 0.019, p = 0.043, respectively). Nineteen out of 21 cases showed full recovery of subretinal fluid in the half energy PDT group with an average treatment period of 1.3 ± 0.8 months and 7 out of 24 cases showed full recovery in the IVB injection group with an average treatment period of 3.2 ± 2.8 months. There was a single case of recurrence in the half energy PDT group and 4 in the IVB injection group. The half energy PDT group showed a meaningful decline in central macular thickness at 1, 3, and 6 months after treatment (p = 0.001, p = 0.005, p = 0.007, respectively) compared to the IVB injection group and showed numerous cases with decline in central macular thickness below the 2 standard deviation from normal values (p = 0.002). Conclusions: Both half energy PDT and IVB injection were effective for the treatment of chronic central serous chorioretinopathy. However, the half energy PDT group comparatively showed better anatomical and functional outcomes. The thinning of central macular thickness below normal value was also observed, thus careful choice of treatment is necessary for patients with chronic central serous chorioretinopathy.

참고문헌 (Reference)

1 신범호, "베바시주맙 안내주입술로 호전된 하층망막박리를 동반한 중심장액맥락망막병증 1예" 대한안과학회 51 (51): 1419-1422, 2010

2 장문희, "만성 중심장액맥락망막병증에서 절반 에너지를 적용한 광역학치료의 효과" 대한안과학회 50 (50): 1326-1333, 2009

3 김정림, "만성 중심장액맥락망막병증 환자에서 짧은 시간의 광역학치료의 효과" 대한안과학회 49 (49): 1078-1086, 2008

4 Verteporfin in Photodynamic Therapy Study Group, "Verteporfin therapy of subfoveal choroidal neovascularization in Age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- VIP report 2" 131 : 541-560, 2001

5 Von Graefe A, "Ueber centrale recidivirende retinitis" 12 : 211-215, 1866

6 Yannuzzi LA, "Type-A behavior and central serous chorioretinopathy" 7 : 111-131, 1987

7 Lai TY, "Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy" 137 : 826-833, 2004

8 Yap EY, "The long-term outcome of central serous chorioretinopathy" 114 : 689-692, 1996

9 Lim JW, "The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy" 249 : 969-974, 2011

10 Gregori-Gisbert I, "Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection" 86 : 407-411, 2011